Published on
May 25, 2023
- 21:31 GMT
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily ...
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD) Efficacy and tolerability data from dose escalation and expansion results inform protocol amendment …
Distribution channels:
Healthcare & Pharmaceuticals Industry
